Journal
CANCER CELL INTERNATIONAL
Volume 18, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12935-018-0533-z
Keywords
FBPase; Cancer; Clinical significance; Mechanism
Categories
Funding
- Medical Scientific Research Foundation of Guangdong Province, China [2016102120351019]
Ask authors/readers for more resources
Cancer is a leading cause of death in both developed and developing countries. Metabolic reprogramming is an emerging hallmark of cancer. Glucose homeostasis is reciprocally controlled by the catabolic glycolysis and anabolic gluconeogenesis pathways. Previous studies have mainly focused on catabolic glycolysis, but recently, FBPase, a rate-limiting enzyme in gluconeogenesis, was found to play critical roles in tumour initiation and progression in several cancer types. Here, we review recent ideas and discoveries that illustrate the clinical significance of FBPase expression in various cancers, the mechanism through which FBPase influences cancer, and the mechanism of FBPase silencing. Furthermore, we summarize some of the drugs targeting FBPase and discuss their potential use in clinical applications and the problems that remain unsolved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available